Clinical Genomics signs China partner for FIT

Clinical Genomics has signed a distribution deal for its colorectal cancer screening technology covering the enormous Chinese market.

Clinical diagnostics company BioChain Group has become the exclusive distributor for the InSure FIT faecal immunochemical technology in China.

BioChain will now run an initial trial to be used as part of the approval package with the China Food and Drug Administration. The company hopes to have the test integrated into the Chinese government’s recently announced China Cancer Screening Feasibility Study.

Clinical Genomics’ screening technology is already being sold around the world, including Australia and the USA. In Australia, the test is offered as part of the BowelScreen program in partnership with Bowel Cancer Australia.

The company said that more than 10 million people have been screened using InSure FIT since 1999.

Clinical Genomics CEO Dr Larry LaPointe said governments around the world are seeking affordable and flexible cancer screening technologies for their communities.

“The Insure ‘brush’ test is easy to use and is designed for large screening programs. This test is ideal for large countries such as China with regional and remote communities that may not otherwise have accessible screening options,” he said.

Clinical Genomics also recently signed a licence agreement with the CSIRO giving it the rights to market the co-developed blood test for bowel cancer ColoVantage Plasma worldwide. The test is designed as an alternative to people who cannot or will not undergo faecal testing.